Sarah Gordon Wild combines extensive experiences in the biotechnology sector with experiences in the investment sector and Capital Markets. She currently also serves as a Non-Executive of Oxford Nanopore Technologies Ltd and Evox Therapeutics, as well as being a Board Member of Lone Pine Capital LLC’s Offshore Funds. There she served as Managing Director, Member of the Management Committee and Member and Senior Healthcare Analyst from 1998 to 2003. Before this, she was a senior biotechnology/healthcare analyst on Wall Street.

Redx is based in Alderly Park in UK and focused on drug discovery and development against cancer and fibrosis.